BCOP Recertification Course
The HOPA Recertification Course assists current oncology pharmacists in meeting the BPS requirement to complete a Preparatory Review/Recertification Course at least once, but no more than three times, during their 7-year BCOP recertification cycle. This course is divided into 6 parts that feature content outlines in addition to webinars and podcasts. Click here to learn more.
The BCOP Recertification course is now available.
This course provides 28.00 BCOP CE hours and 33.50 ACPE CE hours. BCOP credit and ACPE credit will expire on June 19, 2021.
All online, interactive modules require a computer and a reliable internet connection.
If you have questions about these modules, please contact HOPA Education at EducationSupport@hoparx.org.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. ACPE credit must be claimed by June 19, 2021.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of Board Certified Oncology Pharmacist (BCOP) credit. A BCOP statement of credit will be issued only upon completion of a post- activity evaluation form, and post-test, a passing grade of 75% or greater is achieved. BCOP credit must be claimed by June 19, 2021.
Disclosure of Conflicts of Interest
The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict
The Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.